Francisco Pernas, MD
Otolaryngology · Miami, FLNPI 1932309754
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,470 of the $70,031 with a category attached, or 76.4%. Optinose US, Inc. accounts for 90.7% of it on its own, with 23 other manufacturers making up the rest. Among otolaryngology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $200.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$64K
- Intersect ENT, Inc.$1K
- Sanofi$911
- Stryker$889
- GSK$861
- Regeneron Healthcare Solutions, Inc.$748
- plus $2K from 18 others
What the payments were for
- Consulting fees$2,0003%
- Speaking & faculty fees$53,47076%
- Travel & lodging$5,4538%
- Food & beverage$9,07413%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 154 | $63,520 |
| Intersect ENT, Inc. | 8 | $1,114 |
| Sanofi | 30 | $911 |
| Stryker | 14 | $889 |
| GSK | 55 | $861 |
| Regeneron Healthcare Solutions, Inc. | 31 | $748 |
| Aerin Medical Inc. | 10 | $491 |
| Medtronic(2 entities) | 8 | $352 |
| Smith+Nephew | 8 | $343 |
| Acclarent, Inc | 5 | $253 |
| Hikma Pharmaceuticals USA | 6 | $99 |
| Integra Lifesciences Corporation | 4 | $97 |
| Mylan Pharmaceuticals Inc. | 3 | $64 |
| Kaleo, Inc. | 3 | $48 |
| Inspire Medical Systems, Inc. | 1 | $47 |
| Alk-abello, Inc | 2 | $36 |
| Amgen | 1 | $34 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $24 |
| Greer Laboratories, Inc. | 1 | $20 |
| Checkpoint Surgical, Inc | 1 | $19 |
| Novartis | 1 | $18 |
| Aroa Biosurgery Incorporated | 1 | $16 |
| Olympus America Inc. | 1 | $15 |
| Cook Medical LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xhance$61,578
- PROPEL$1,158
- SINUVA$1,013
- VIVAER STYLUS$267
- RHINAER STYLUS$267
- SCOPIS ENT$263
- ADHERUS AUTOSPRAY DURAL SEALANT$169
- UNIVERSAL NEURO 3$169
- NA$169
- VivAer$157
- RhinAer$157
- SONOPET IQ$145
- NUCALA$119
- TruDi Nav Cable$106
- STEALTHSTATION S8 PLATFORM$101
How this compares
$70,031 in reported general payments places this provider in the 95th percentile of 586 otolaryngology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $52,438 |
| XhanceFluticasone Propionate | 29 | $32,098 |
| Fluocinolone Acetonide Oil | 244 | $12,888 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 70 | $8,699 |
| Azelastine Hcl | 270 | $8,254 |
| Fluticasone Propionate | 328 | $5,083 |
| Hydrocortisone-Acetic AcidHydrocortisone/Acetic Acid | 44 | $4,032 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 34 | $3,204 |
| Epinephrine | 14 | $1,746 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 33 | $1,663 |
| Omeprazole | 94 | $1,334 |
| Ipratropium Bromide | 91 | $1,285 |
| Montelukast Sodium | 178 | $1,206 |
| Mupirocin | 109 | $898 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 95 | $885 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $63,520 | $32,09829 claims |
| Hikma Pharmaceuticals USAEpinephrine | $99 | $1,74614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 otolaryngology providers in Florida.
Other otolaryngology in Miami
- Maria SuurnaMiami$189K
- Agustin ArrietaMiami$95K
- Adrien EshraghiMiami$41K
- Michael HofferMiami$24K
- Corinna LevineMiami$16K
- Jason LeibowitzMiami$13K
- Donald WeedMiami$8K
- Cecelia DamaskOrlando$707K
- Ralph TufanoSarasota$469K
- Franklin RimellFort Myers$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.